Skip to main content
Premium Trial:

Request an Annual Quote

GenomOncology, CompanionDx to Partner on NGS-based Cancer Panels

NEW YORK (GenomeWeb News) – CompanionDx and GenomOncology will develop a series of next-generation sequencing-based assays for cancer, the companies said today.

CompanionDx will use GenomOncology's GO Clinical Workbench software to develop a clinical report from the raw sequencing data.

The GO Clinical Workbench analysis is fully traceable and includes a decision support tool for the interpretation of somatic mutations.

CompanionDx is a CLIA-certified laboratory with locations at the Texas Medical Center in Houston and in Honolulu. It provides both personalized pharmacogenomics and cancer companion diagnostic testing.

"As we develop new tests that leverage next-generation sequencing, we require a solution that meets our current needs but is scalable over time," CompanionDx President David Lasecki said in a statement. "GenomOncology's platform and services will allow us to efficiently add new cancer panels and expand our testing options to best serve our clients."